- Home
- IDA vs IBRX Comparison
IDA vs IBRX Comparison
Compare IDA & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IDA | IBRX |
|---|---|---|
| Founded | 1915 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.5B |
| IPO Year | 1998 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IDA | IBRX |
|---|---|---|
| Price | $139.75 | $7.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $142.86 | $12.57 |
| AVG Volume (30 Days) | 452.2K | ★ 9.2M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 7.27 | ★ 38.71 |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $1,746,972,000.00 | $113,288,000.00 |
| Revenue This Year | $10.92 | $88.59 |
| Revenue Next Year | $7.71 | $131.15 |
| P/E Ratio | $24.04 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $122.30 | $1.95 |
| 52 Week High | $154.91 | $12.43 |
Technical Indicators
Market Signals| Indicator | IDA | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 49.79 |
| Support Level | $137.54 | $6.68 |
| Resistance Level | $144.83 | $8.46 |
| Average True Range (ATR) | 3.41 | 0.41 |
| MACD | -0.82 | 0.04 |
| Stochastic Oscillator | 6.23 | 58.28 |
Price Performance
Historical ComparisonAbout IDA IDACORP Inc.
Idacorp is a holding company for Idaho Power. Idacorp is a vertically integrated utility that generates, transmits, and distributes electricity to 670,000 customers in southern Idaho and eastern Oregon. The utility owns 1.8 gigawatts of hydro generation, 400 MW of coal generation, 1.4 GW of natural gas generation, and 300 MW of energy storage.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.